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CASE PRESENTATION
A 51-year-old white woman was admitted to the Johns Hopkins
Hospital with a three-day history of diarrhea characterized by three to four
loose bowel movements per day associated with nausea, vomiting, abdom-
inal cramping, fever, epistaxis, and diminished urine output. During the 24
hours prior to admission, she had produced no urine. She denied dysuria,
hematuria, or flank pain. She had not noted either a rash or joint or
muscle pains, nor had she had a skin or pharyngeal infection. Aside from
well-controlled hypertension and a history of an uncomplicated percuta-
neous coronary angioplasty two years earlier, she had been well before the
onset of this illness. She denied any history of urinary tract symptoms or
abnormalities. No other members of her family had fallen ill.
The patient had been seen for a routine evaluation one month prior to
the onset of the present illness. At that time, her blood urea nitrogen was
13 mg/dl; the serum creatinine was 0.8 mg/dl with normal electrolytes. The
white blood cell count was 5.5 x 106/ml; hemoglobin, 13.3 g/dl with a
hematocrit of 41%. The platelet count was 291 x 106/ml.
At the time of admission, the patient was pale, alert, and in no acute
distress. Her blood pressure was 148/85 mm Hg; heart rate, 85 beats/min;
respiratory rate, 22 breaths/min; temperature 39°C. A pronounced diffuse
petechial rash was noted. No adenopathy was present, nor were muscle or
joint tenderness. Examination revealed a normal heart and lungs. The
abdomen was soft and had mild, diffuse tenderness without rebound
tenderness. Rectal examination was normal; stool was positive for occult
blood. There was no flank tenderness. No peripheral edema was noted. At
no time during her hospital stay was there any hemodynamic compromise.
At the time of admission, the blood urea nitrogen was 110 mg/dl; serum
creatinine, 11.3 mg/dl; serum sodium, 131 mEq/liter; and serum potas-
sium, 4.9 mEq/liter. The serum bicarbonate concentration was 19 mEq/
liter. Hemoglobin was 10.1 g/dl with a hematocrit of 28.2%. The platelet
count was 29 x 106/ml. The prothrombin time and partial thromboplastin
time were normal. No fibrin degradation products were present. The white
blood cell count was 10.7 x 106/ml, with 53% polymorphonuclear neutro-
phils, 23% bands, 14% lymphocytes, 7% basophils, and 3% atypical
lymphocytes. The serum lactate dehydrogenase concentration was 8000
mg/dl and the blood smear showed numerous schistocytes. Catheterization
produced 15 ml of urine. The unspun specimen showed numerous white
blood cells and 2–5 red blood cells/high-powered field; bacteria were
present. Renal ultrasound examination revealed two kidneys of normal
size, without evidence of obstruction.
Within the first 24 hours of admission, gram-negative rods grew in 3
blood cultures and in the urine culture. The organisms later were
identified as Enterobacter aerogenes with broad antibiotic sensitivity. The
patient was given antibiotics. Hemodialysis every other day was initiated.
Her fever resolved within 24 hours and all evidence of hemolysis ceased
within 4 days. Thrombocytopenia improved; the platelet count returned to
normal one week after institution of antibiotic therapy. However, com-
plete anuria persisted. On day 10 of her hospital stay, a diagnostic
percutaneous renal biopsy was performed.
The biopsy, which will be discussed in detail by Dr. Racusen, showed
evidence of acute infectious interstitial nephritis (pyelonephritis). In
addition, findings on electron microscopy were consistent with acute
thrombotic microangiopathy.
Three days after the renal biopsy was performed, the patient produced
small amounts of urine containing many white blood cells. The urine
output continued to increase, and the urinalysis showed copious white
blood cells throughout her hospital stay. Dialysis was discontinued, and
the patient was discharged 10 days after the renal biopsy. Followup one
week later showed a serum creatinine of 2.0 mg/dl and a blood urea
nitrogen concentration of 18 mg/dl. She failed to keep further appoint-
ments.
This case demonstrates the clinical features of both pro-coagulant and
pro-inflammatory endothelial cell activation. Massive mobilization of von
Willebrand factor and P-selectin by calcium-mobilizing agonists is likely to
play the predominant role in platelet thrombus formation, so common in
patients with thrombotic microangiopathy, while recruitment of inflam-
matory cells is mediated by a different, NFkB-dependent mechanism
mechanism, reflected in this case by interstitial leukocyte infiltration.
Renal biopsy
DR. LORRAINE C. RACUSEN (Associate Professor of Pathology, The Johns
Hopkins University School of Medicine, Baltimore, Maryland, USA): The
biopsy specimen consists mainly of cortex, with a small amount of medulla.
At low power, the very cellular appearance of the cortical and medullary
interstitium is immediately evident. Glomeruli are not hypercellular, but
there is periglomerular inflammation. At higher power, the interstitial
infiltrate consists predominantly of mononuclear cells, with plasma cells,
lymphocytes, and monocyte/macrophages. Many polymorphonuclear leu-
kocytes are also found in the interstitium (Fig. 1A); in some areas these
are very numerous, forming mini-abscesses. In addition, occasional foci of
eosinophil accumulation are observed. Scattered throughout the specimen
are many large and potentially obstructing cellular casts (Fig. 1A)
containing polymorphonuclear leukocytes within the tubules. There is
localized tubular epithelial cell injury with vacuolization, tubular cell loss,
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and sloughing of epithelial cells into the lumen. Special stains show
intrusion of inflammatory cells through the basement membrane into
tubules, at times lifting the epithelial cells from the basement membrane.
Prominent interstitial edema is present without evidence of fibrosis.
Examination of glomeruli shows normal cellularity and open capillary
loops. The silver stain shows some areas of localized interposition. Subtle
endothelial cell enlargement with some edema and vacuolization is
evident. Patchy arteriolar smooth muscle cell vacuolization is also ob-
served. Immunofluorescence showed no deposition of immunoglobulins
or complement components within the glomeruli.
Ultrastructural examination shows no glomerular cell proliferation,
inflammatory cells, or electron-dense deposits. However, there is wide-
spread evidence of glomerular endothelial and epithelial cell injury (Fig.
1B). Endothelial cell swelling is evident both at the capillary loop hilum
and around the circumference of the glomerular capillaries. The normal
endothelial cell fenestrae have been lost. In several areas, endothelial cells
have lifted away from the basement membrane, and flocculent material
has accumulated between the cells and the glomerular capillary basement
membrane. Also evident are extensive epithelial cell foot process efface-
ment and some microvillous transformation of epithelial cells.
The changes on biopsy are consistent with a severe interstitial nephritis,
probably of infectious etiology. The glomerular changes are consistent
with endothelial cell activation. This type of endothelial cell injury
typically is seen in thrombotic microangiopathy, although the changes are
less severe than those usually seen in the hemolytic-uremic syndrome.
DISCUSSION
DR. BARBARA J. BALLERMANN (Associate Professor of Medicine,
Johns Hopkins University School of Medicine): My discussion today
addresses the mechanisms whereby endothelial cell activation by
bacterial toxins and inflammatory mediators contributed to the
Fig. 1. (A) Hematoxylin-eosin-stained renal
interstitium showing marked inflammatory cell
infiltration and a potentially obstructing
tubular cast. (B) Electron micrograph of a
glomerular capillary loop showing markedly
swollen endothelial cells that nearly obliterate
the capillary lumen. Endothelial cells have
detached from the basement membrane
(arrows). Flocculant material has accumulated
between the glomerular capillary basement
membrane and the endothelial cell.
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dramatic presentation and clinical course of this patient. Endo-
thelium is the principal barrier to cell movement from the
circulation into tissues and usually serves an anticoagulant func-
tion. Immune injury often prompts endothelial cell swelling and
vacuolization. Such ultrastructural changes are associated with
increased expression of leukocyte adhesion molecules, chemokine
elaboration, and augmented procoagulant activity. A good exam-
ple of the ultrastructural appearance of activated glomerular
capillary endothelial cells is shown in the electron micrograph of
the case presented today (Fig. 1B). Glomerular endothelial cell
swelling is a nonspecific reaction, although we have known for 3
decades that in the hemolytic-uremic syndrome [1] and pre-
eclampsia [2] these changes can be severe enough to reduce
capillary perfusion. Activation of glomerular endothelium in
immune-complex-mediated proliferative glomerulonephritis oc-
curs in areas of subendothelial cell immune-complex or antibody
deposition, where evidence for endothelial cell proliferation is
also frequently detected [3].
The clinical observation of platelet consumption and formation
of schistocytes in cases of thrombotic microangiopathy results
from activation of endothelial cell pro-coagulant activity. Leuko-
cyte influx into the kidney in response to infection, or into
glomeruli in cases of glomerulonephritis, reflects activation of
endothelial cell leukocyte recruitment mechanisms. Local activa-
tion of pro-coagulant and leukocyte recruitment mechanisms
coexist in most cases of inflammatory endothelial cell activation,
whereas procoagulant mechanisms predominate in the throm-
botic microangiopathies. The case presented today lends itself
nicely to the discussion of both phenomena, given the concomi-
tant evidence for acute infectious interstitial nephritis with mas-
sive infiltration of the kidneys by inflammatory cells and the
clinical and electron microscopic evidence for thrombotic mi-
croangiography. As I stated, my goal is to provide a comprehen-
sive overview of the mechanisms of endothelial cell activation.
Mechanisms of endothelial cell activation
Endothelial cell activation can be direct, for example, when
anti-endothelial cell antibodies result in complement fixation at
the endothelial cell surface, or when bacterial toxins or toxic
pharmacologic agents act on endothelial cells. Activation also can
result from the release of cytokines by neighboring cells, for
instance, in response to infection or antigen-antibody complex
formation. Circulating anti-endothelial cell antibodies are some-
times observed in patients with vasculitis [4], scleroderma [5], and
possibly also antineutrophil-cytoplasmic-antibody (ANCA)-asso-
ciated vasculitis [6]. Although endothelial cells do not express the
most common ANCA antigens, proteinase 3 and myeloperoxi-
dase, these enzymes can associate non-covalently with the glyco-
calyx of endothelial-cell plasma membrane after being released
from degranulating neutrophils [7], where they then are subject to
ANCA binding with consequent complement-dependent endo-
thelial cell lysis. The display of ANCA antigens at the plasma
membrane surface of active neutrophils results in an oxidative
burst [8]. Under those circumstances, endothelial cell injury is
caused by oxygen-free radicals, proteases, and lipid mediators.
Binding of anti-endothelial cell antibodies to their target anti-
gens [9], subendothelial cell immune-complex deposition, for
instance, in SLE and poststreptococcal glomerulonephritis [10,
11], or interaction of antibodies with the glomerular basement
membrane [12] leads to complement fixation and complement-
mediated endothelial cell injury [13]. Some of the products of the
activated complement cascade interact directly with endothelial
cells to activate endothelial cell procoagulant and leukocyte
adhesion functions (Fig. 2A). Receptors for the first component of
complement, C1q [13], are expressed by leukocytes, platelets, and
mesangial and endothelial cells [14, 15]. In myeloid and mesangial
cells, C1q receptors facilitate Fc receptor-dependent immune-
complex phagocytosis and oxygen-free-radical formation [16]. In
endothelial cells, which only express Fc receptors when primed by
interferon g [17, 18], antigen-antibody-fixed C1q nevertheless
stimulates endothelial cell expression of the neutrophil adhesion
molecules E-selectin, ICAM-1, and VCAM-1 by activating C1q
receptors [19], even in the absence of other co-stimulants.
Activation of the classical complement cascade by antigen-
bound IgG and IgM antibodies releases the anaphylatoxins C3a,
C4a, and C5a, which are produced by proteolytic cleavage of the
inactive C4, C3, and C5 complement components. In endothelial
cells, activation of C5a receptors rapidly mobilizes P-selectin to
the cell surface and induces von Willebrand factor (vWF) secre-
tion [20]. Both pre-formed vWF and P-selectin, stored in endo-
thelial cell Weibel-Palade bodies, are rapidly mobilized by several
calcium-mobilizing agonists in addition to C5a, for instance,
thrombin, histamine, and leukotriene C4 [21].
The ultimate product of complement activation is the mem-
brane attack complex C5b-9, which forms large pores in the
plasma membrane [22]. In patients with vasculitis, C5b-9 has been
localized to endothelial cells [23], and C5b-9 mediates endothelial
cell destruction following xenotransplantation [24]. Large quanti-
ties of C5b-9 produce frank endothelial cell lysis [25]. Two
powerful inhibitors of membrane-attack-complex formation,
CD59 and HRF (homologous restriction factor) are expressed by
endothelial cells, including renal glomerular and peritubular
endothelial cells [26–28]. These proteins protect endothelial cells
from complement-mediated damage in species-specific fashion.
Indeed, human CD59 protects against xenoantibody-mediated
endothelial cell lysis. This finding suggests that the xenotransplan-
tation barrier might be overcome, in part, by using organs from
animals transgenic for human CD59 [29]. Inhibitors of earlier
steps in the complement-activation cascade, including decay ac-
celerating factor, which inhibits C3 and C5 convertase function,
are also expressed by endothelial cells and are similarly protective
against complement activation [30]. Complement activation at the
endothelial surface does not always lead to cell lysis, probably
because of these endothelial complement inhibitors. Conse-
quently, sublytic effects of C5b-9 have been described, most
prominent among them the induction of procoagulant activity
[31]. The C5b-9 complex stimulates vWF release and cell-surface
P-selectin expression [32] and markedly increases endothelial cell
tissue factor production (Fig. 2A) [33]. In addition, C5b-9 stimu-
lates E-selectin and ICAM-1 expression [34].
Tumor necrosis factor a (TGFa) and interleukin-1b (IL-1b)
are central mediators of endothelial cell activation. They stimu-
late endothelial cells to secrete chemokines and express leuko-
cyte-adhesion molecules, and they turn endothelium into a pro-
coagulant surface [35, 36]. Both TNFa and IL-1b are secreted by
tissue macrophages and other resident cells (Fig. 2B) in response
to bacterial endotoxin (lipopolysaccharide, LPS); this response is
markedly augmented by interferon [37]. In addition, phagocytosis
of opsonized particles, Fc receptor cross-linking [38], IgG and IgA
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immune complexes [39], and C5a [40] all stimulate TNFa secre-
tion. TNFa is also secreted by T-lymphocytes during the process
of T-cell-receptor engagement with major histocompatibility com-
plex (MHC) class-II bound antigens [41] and by activated poly-
morphonuclear neutrophils [42]. Interleukin-1b is synthesized by
monocyte/macrophages; potent stimuli for its synthesis are LPS
and macrophage contact with CD41 T-cells [43]. Also, TNFa
strongly stimulates IL-1b synthesis by macrophages and by a
number of other cell types, including endothelial cells. Studies
also have shown the presence of TNFa and IL-1b in resident
glomerular cells in glomerulonephritis both in experimental ani-
mals and in patients [44–46]. In the patient presented today, the
induction of inflammatory cytokines by bacterial LPS probably
was responsible, at least in part, for endothelial cell-dependent
recruitment of lymphocytes into the interstitium. Whether cyto-
kine production was sufficient to explain activation of glomerular
Fig. 2. Schematic representation of the
components of endothelial cell activation. (A)
Activation of the complement cascade in the
vicinity of endothelial cells leads to liberation of
complement components that can interact
directly with endothelial cells. (B) TNFa is
produced by a number of cells, including
endothelial cells, in response to diverse stimuli.
TNFa in turn stimulates IL-1b release by
endothelial cells and macrophages. (C)
Consequences of endothelial cell activation by
TNFa and IL-1b include leukocyte recruitment,
expression of procoagulant activity, and
alterations in mediator release. Abbreviations
are: MCPs, monocyte chemotactic proteins;
PECAM-1, platelet endothelial cell adhesion
molecule-1.
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endothelial cells or whether an additional, unidentified bacterial
toxin participated in promoting glomerular endothelial cell pro-
coagulant activity is not known.
In endothelial cells, TNFa and IL-1b activate the nuclear
transcription factor NF-kB/Rel, thereby triggering the transcrip-
tion of a number of genes that control the endothelial cell
inflammatory response [47]. Factor NF-kB/Rel is a dimeric com-
plex consisting of NF-kB and Rel subunits, the former ; 50 kD,
the latter ; 65 kD in size. The 65 kD Rel component exists
preformed in endothelial cells, either bound to a larger (; 105
kD) precursor of NF-kB, which requires proteolytic cleavage to
the ; 50 kD form for activation, or the 50 kD/65 kD NF-kB/Rel
complex is bound to IkB-a, which masks the NF-kB nuclear
targeting sequence. Processing of the 105 kD precursor of NF-kB
or degradation of IkB-a via the ubiquitin/proteasome pathway
results in activation [48]. Phosphorylation of IkB-a targets it for
degradation [47], and inhibition of IkB-a phosphorylation pre-
vents NF-kB/Rel activation in endothelial cell [49]. Also, nitric
oxide inhibits IkB-a degradation and NF-kB/Rel activation [50].
Upon activation, the NF-kB/Rel dimer rapidly moves to the
nucleus, where it interacts with a number of promoters, among
them those for leukocyte adhesion molecules E-selectin,
VCAM-1, and ICAM-1, procoagulant molecules like tissue factor,
and other components of the inflammatory response, for instance,
the IL-8 promoter [47].
Consequences of endothelial activation
Leukocyte recruitment. The actions of TNFa and IL-1b on
endothelial cells are diverse, stimulating procoagulant activity,
leukocyte adhesion, and mediator release (Fig. 2C). Leukocyte
adhesion to endothelium is a necessary step for facilitating
recruitment of leukocytes into areas of inflammation. Distinct
adhesion molecules and chemokines regulate this process for
different leukocyte subsets. Although the specific molecules in-
volved differ depending on the type of inflammatory response, the
overall mechanism is similar for all leukocytes and involves
successive interactions among three families of ligand-receptor
pairs. First, selectins appear on the endothelial cell surface and
bind highly glycosylated counterreceptors, also referred to as
mucins, on leukocytes. This interaction is of relatively low affinity
and, in the absence of other stimuli, cannot support leukocyte
migration into tissues. The selectin-mucin interaction brings leu-
kocytes in close contact with chemokines clustered on the surface
of endothelial cells and leads to engagement of leukocyte chemo-
kine receptors. Chemokine receptors in turn transform leukocyte
integrins from low- to high-affinity receptors, and also stimulate
further synthesis of integrins. These integrins then find their
respective counterreceptors, cell adhesion molecules (CAMs), on
the endothelial cell surface and bind to them with very high
affinity. This last step allows leukocytes to flatten and spread on
the endothelial cell monolayer. Diapedesis of leukocytes through
the endothelial cell monolayer depends on chemokines and
integrin-CAM interactions. I now will review the endothelial cell
component of the process of leukocyte recruitment.
Chemokines stimulate movement of leukocytes to areas of
inflammation. Chemokines have been placed into two broad
groups, alpha and beta [51]. Genes encoding the alpha chemokine
family, clustered on human chromosome 4, are primarily involved
in neutrophil chemotaxis. The most studied member of this group
is interleukin-8 (IL-8), formerly known as neutrophil activating
protein 1. Genes of the beta family cluster on human chromosome
17, and their products act principally on monocytes. Monocyte
chemotactic proteins -1, -2, and -3 (MCP-1,2,3) as well as RANTES
are members of this group.
Stimulation of endothelial cells by TNFa, IL-1b, and LPS
results in the synthesis and release of IL-8 and MCP-1 [52]. These
chemokines remain confined to the endothelial cell surface, where
they are presented to leukocytes in characteristic clusters [53]. As
is the case with other endothelial cell responses to TNFa, IL-8
transcription is dependent on NF-kB activation [54]. Endothelial
cell IL-8 synthesis is also stimulated by histamine [55] and contact
with fibrin [56], and activated monocytes stimulate endothelial cell
IL-8 synthesis by presenting cell-surface, lectin-bound IL-1a to
endothelial cells during cell-cell adhesion [57]. Other mediators
involved in the inflammatory reaction, for instance C5a [58],
leukotriene B4 [59], and platelet activating factor [60], also have
chemotactic activity towards leukocytes, often exhibiting a syner-
gistic effect with the chemokines and also with the cytokines
TNFa and IL-1b [61]. Chemokine-stimulated leukocyte chemo-
taxis requires expression of CAMs by endothelial cells, and
synergistic effects between inflammatory cytokines and chemo-
kines on leukocyte chemotaxis likely relate to cytokine-stimulated
CAM expression on endothelial cells [60]. Conversely, chemo-
kines are inactive if adhesion molecules are not expressed, or if
they are shed from either leukocyte or endothelial cell surfaces.
Indeed, both IL-8 and C5a can inhibit and even reverse neutrophil
adhesion to endothelium because of shedding of L-selectin from
the neutrophil surface in response to low concentrations of these
mediators [62]. By contrast, high concentrations of chemokines at
the surface of endothelial cells increase leukocyte integrin expres-
sion and affinity, thus promoting adhesion. To explain the dual
effect of chemotactic substances, Rot has argued that stimulation
of leukocyte chemotaxis requires clustering of chemokines on the
apical surface of endothelial cells, while release of chemokines
inhibits leukocyte adhesion [61]. The model would predict that
leukocyte activation remains confined to the endothelial cell
surface, and that activation of non-adherent leukocytes does not
readily occur.
The complement components C1q, C5a, and C5b-9, and the
inflammatory cytokines TNFa and IL-1b stimulate expression of
leukocyte adhesion molecules at the apical surface of endothelial
cells [47, 63]. In vivo, adhesion molecules frequently are expressed
in tissues during inflammation, including renal glomerular and
tubulointerstitial diseases [64, 65]. The leukocyte-endothelial cell
interaction occurs in a stepwise fashion [63]. First, low-affinity
binding between selectins and their counterreceptors, the mucins,
faciliates “rolling” of leukocytes along the apical surface of
endothelial cells. During this phase, leukocytes encounter IL-8
and other chemokines clustered at the endothelial cell surface.
Chemokines in turn stimulate expression of leukocyte integrins,
their clustering in uropods, and conformational changes that
increase integrin affinity. The integrins expressed at the leukocyte
cell surface then bind to endothelial cell adhesion molecules
belonging to the immunoglobulin gene family (ICAMs, VCAM-1,
and PECAM-1) [64]. Subsequent diapedesis of the leukocytes
across the endothelium depends on the chemokine stimulus. The
coordinated expression of adhesion molecules and their specific
counterreceptors is necessary for the successful and selective
recruitment of leukocytes to sites where their actions are required.
The L-, P-, and E-selectins mediate the initial low-affinity
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interaction of leukocytes with endothelial cells [66]. Although
mice deficient in P-, E-, and L-selectin fail to exhibit increased
susceptibility to infection [67–69], the rate of leukocyte recruit-
ment in response to inflammatory stimuli is reduced in such
animals. The extracellular portion of selectins comprises a calci-
um-dependent lectin domain, an epidermal-growth-factor-like
domain, and several short repeats homologous to complement-
binding proteins [66]. The remainder is composed of a single
transmembrane spanning domain and a short cytoplasmic tail.
The lectin domain binds carbohydrate moieties of mucin-like
glycolipids and proteoglycans on adjacent cells. L-selectin is
expressed only by hematopoietic cells [70]. After the initial
adhesion, L-selectin is cleaved rapidly upon activation of leuko-
cytes with endothelial-cell-derived IL-8 and other chemokines
[71]. As I said, P-selectin is constitutively expressed and stored in
endothelial cell Weibel-Palade bodies [72]. Mobilization of Wei-
bel-Palade bodies in response to mediators like C5a, thrombin,
histamine, the membrane attack complex, and bacterial toxins
results in insertion of P-selectin into the apical plasma membrane
of the endothelial cell and is associated with vWF release [20, 32].
Endothelial cell P-selectin expression is also regulated at the
transcriptional level by LPS and TNFa [73]. Expressed only by
endothelial cells, E-selectin requires transcriptional activation by
inflammatory cytokines like TNFa, IL-1b, interferon g, or LPS
[47].
The leukocyte tetrasaccharide sialyl LewisX is a major ligand
for E- and P-selectins, and several heavily glycosylated proteins,
the mucins, have been identified as high-affinity selectin ligands
[74]. On postcapillary venule endothelial cells, CD34, a constitu-
tively expressed mucin-like protein, acts as the L-selectin receptor
[75]. By contrast, L-selectin-mediated leukocyte adhesion to other
endothelial cells does not occur unless the endothelial cells have
been activated by cytokines [76, 77]. This finding suggests that
cytokines induce expression of as-yet-uncharacterized L-selectin-
specific counterreceptors in endothelial cells.
Spreading and diapedesis of leukocytes across endothelial cell
monolayers depend on interactions between leukocyte integrins
and their counterreceptors on endothelial cells. Integrins are
heterodimeric proteins composed of a and b subunits, which
interact with their ligands in a calcium-dependent manner [78].
The leukocyte integrins contain predominantly b1 (CD29) and b2
(CD18) subunits with various a subunit partners. Ordinarily,
leukocyte activation by chemokines, which augment integrin
transcription and markedly increase integrin affinity, is necessary
to stimulate adhesion. The receptors for leukocyte integrins at the
endothelial cell surface are intercellular adhesion molecules-1 and
-2 (ICAM-1 and -2) and vascular cell adhesion molecule-1
(VCAM-1). Both VCAM-1 and ICAM-1 are essentially absent in
the unstimulated state, but their abundance at the cell surface is
markedly increased upon transcriptional activation by cytokines
[47, 78]. Integrin-CAM interactions participate in leukocyte re-
cruitment in several experimental models of glomerulonephritis,
and in ANCA-associated vasculitis [79–82].
The procoagulant state. Normal endothelium produces several
substances, for instance prostacyclin, nitric oxide, thrombomodu-
lin, protein S, and tissue-type plasminogen activator (t-PA), which
prevent platelet activation and fibrin clot formation [83]. In
addition, endothelial cells are covered, at their apical surface, by
a heavy glycocalyx, which contains abundant heparan sulfate
proteoglycans that bind antithrombin III, an inhibitor of throm-
bin-mediated clot formation. In the activated state, the endothe-
lium can synthesize mediators that counteract the anticoagulant
systems, among them vWF, plasminogen activator inhibitor
(PAI), and tissue factor. Interestingly, PAI-I, found predomi-
nantly basolaterally in quiescent endothelial cells, is found apically
in activated endothelial cells. Injury and cytokine stimulation
suppress anticoagulant properties and augment those that favor a
procoagulant state [83]. Platelet aggregation tends to predomi-
nate in the thrombotic microangiopathies, particularly in patients
with the hemolytic-uremic syndrome, while fibrin deposition
predominates in most forms of immune-complex-mediated glo-
merulonephritis [84, 85].
The von Willebrand factor, critically important in promoting
platelet adhesion, is a multimeric glycoprotein stored in Weibel-
Palade bodies of endothelial cells, where it co-localizes with
P-selectin [24, 86]. Massive release of vWF from these granules
probably is the most important mechanism leading to platelet
aggregation in the thrombotic microangiopathies. Megakaryo-
cytes also produce vWF, which is stored in the a granules of
platelets. Endothelial-cell-derived vWF is also found in the sub-
endothelial matrix, and both endothelial-cell- and platelet-derived
vWF act as carriers for factor VIII in plasma [86]. With massive
release, vWF binds to the platelet receptor GP Ib-IX-V, which in
turn activates the platelet integrin aIIbb3; IIbb3 is responsible for
platelet adhesion and spreading [87]. The platelet activation/
adhesion response is amplified by vWF factor release from
platelets and by thrombin.
Rapid mobilization of vWF from endothelial cells is induced by
thrombin, leukotrienes, serotonin, platelet activating factor
(PAF), and C5a [20, 21, 88]. All these mediators stimulate
intracellular calcium mobilization and consequent exocytosis of
stored vWF. Exocytosis of vWF from endothelial cells generally is
coupled to mobilization of P-selectin to the cell surface [21].
Vasopressin, acting via the adenylate cyclase-coupled V2 receptor,
also stimulates endothelial-cell vWF release, although this re-
sponse appears to be indirect, involving vasopressin-stimulated
PAF release from monocytes [89]. In patients with the hemolytic-
uremic syndrome, augmented endothelial and platelet vWF re-
lease accounts for platelet aggregation in microvessels, the con-
sequent thrombocytopenia, and hemolysis [90, 91].
Two short-lived endothelial-cell-derived inhibitors of platelet
aggregation are nitric oxide (NO) and prostacyclin [92, 93].
During endothelial cell injury or activation, platelet aggregation
also can increase if production of these inhibitors falls. During
endothelial cell activation by inflammatory cytokines, the respec-
tive isoenzyme responsible for production of each of these
mediators changes. Cyclooxygenases (PGH synthases 1 and 2) are
rate-limiting to prostaglandin formation. In quiescent, differenti-
ated endothelial cells, little or no PGH synthase 2 is expressed, but
PGH synthase 2 is dramatically upregulated by IL-1a and LPS
[93]. Wu postulated that PGH synthase 2 is responsible for
sustained prostacyclin release during immune activation of endo-
thelial cells [93].
Constitutively expressed nitric oxide synthase (eNOS), which
converts arginine to citrulline, liberating NO in the process, is
found in all differentiated endothelial cells [92, 94]. The eNOS
activity is calcium dependent and produces NO in response to
several agonists, among them thrombin, bradykinin, PAF, and
histamine [95]. TNFa destabilizes eNOS mRNA and dramatically
reduces eNOS activity in endothelial cells upon stimulation with
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inflammatory cytokines [96]. In contrast to their effect on eNOS,
both TNFa and IL-1b markedly increase inducible nitric oxide
synthase (iNOS) expression in endothelial cells [97, 98]; this effect
is abrogated by glucocorticoids and by TGF-b1 [97]. Thus, in
activated endothelial cells, regulated NO synthesis from eNOS is
abrogated, but sustained NO liberation from iNOS is stimulated.
Therapeutic infusion of prostacyclin analogues in patients with
the hemolytic-uremic syndrome [99], in NZB/WF1 mice with
immune-complex-mediated glomerulonephritis [100], and in rats
with anti-Thy-1-mediated glomerulonephritis [101] has been at-
tempted, but evidence convincingly demonstrating a salutary
reduction in intraglomerular platelet and fibrin deposition has not
been found [88]. In a model of nephrotoxic serum nephritis in
rats, inhibition of NO synthesis was associated with increased
proteinuria and markedly increased intraglomerular platelet dep-
osition, suggesting that in fact NO might counteract aggregation
in this model [102]. In addition, in anti-Thy-1-mediated glomer-
ulonephritis in rats [103] expression of eNOS and iNOS is
increased, the former possibly due to TGF-b1 activation of eNOS
transcription in endothelial cells [104].
Another important factor critical in promoting coagulation is
thrombin. Thrombin-endothelial cell interactions inhibit throm-
bin activity in the absence of endothelial cell activation, but
thrombin also can potentiate endothelial cell activation by inflam-
matory cytokines. Active thrombin is formed by factor Xa- and
V-dependent cleavage of prothrombin. Thrombin stimulates
platelet aggregation and fibrin formation from fibrinogen, and it
activates coagulation factors V, VII, and XIII. Thrombin also
activates specific endothelial cell receptors to stimulate release of
prostacyclin, NO, and vWF. Healthy endothelial cells strongly
inhibit the procoagulant activity of thrombin through thrombo-
modulin and antithrombin III [88].
Thrombomodulin, an abundant integral membrane protein and
potent inhibitor of coagulation [105], is expressed by all endothe-
lial cells, including those in the kidney [106]. Active thrombin
associates with thrombomodulin and Protein S at the endothelial
cell surface; in this complexed form, it activates Protein C, a
powerful protease for factors V and VIII [107]. Thus, when
thrombomodulin is highly expressed, it disables the fibrin-forming
function of thrombin and instead turns thrombin into an inhibitor
of its own formation. The thrombin-thrombomodulin complex is
internalized and degraded after thrombin binding [106]. Endothe-
lial-cell activation by TNFa and IL-1b markedly suppresses
thrombomodulin activity through rapid internalization and deg-
radation of cell-surface thrombomodulin [108], and via reduced
thrombomodulin transcription [109].
Tissue factor, the initiator of the extrinsic coagulation pathway,
is expressed in most tissues, but not normally by endothelial cells
[110]. In endothelial cells, the tissue factor gene is under the
control of an NF-kB-inducible promoter [111] and is therefore
activated by TNFa and IL-1b. In addition, thrombin increases
tissue factor abundance at the apical surface of the endothelial
cell by increasing tissue factor gene transcription [112]. To what
degree tissue factor expression by activated glomerular endothe-
lial cells plays a role in promoting fibrin deposition is not yet clear.
Nevertheless, abundant tissue factor is found in glomeruli during
immune-complex-mediated glomerulonephritis, and particularly
in crescentic glomerulonephritis [113].
An inhibitor of tissue factor, tissue factor pathway inhibitor
(TFPI) is produced by megakaryocytes and by endothelial cells
[83, 114]. This inhibitor is released acutely from a stored pool
(distinct from Weibel-Palade bodies) in response to thrombin
[115], but TFPI transcriptional rate and secretion are unaffected
by inflammatory cytokines [116]. Patients with active thrombotic
thrombocytopenic purpura (TTP) have reduced circulating levels
of TFPI [117]; this finding suggests a role for increased consump-
tion or deficiency of this factor in TTP. Whether a deficiency of
TFPI played a role in promoting intravascular platelet consump-
tion in the patient presented today is not known.
The plasminogen-plasmin system is critical for the rapid disso-
lution of any fibrin strands deposited inappropriately at the apical
surface of endothelial cells. Further, this system aids in matrix
degradation during cell migration [118]. Cell-surface plasminogen
receptors, abundantly expressed on endothelial cells [119], bind
plasminogen and facilitate cleavage by t-PA, also immobilized at
the endothelial surface by specific receptors [120]. Urokinase-type
plasminogen activator (u-PA) also is synthesized by unstimulated
endothelial cells, albeit in much lower abundance than is t-PA
[121]. In quiescent endothelial cells, u-PA tends to remain con-
fined to the subendothelial cell compartment. Endothelial cells
also produce powerful inhibitors of t-PA, plasminogen activator
inhibitor-I and -II (PAI-I, PAI-II) [120, 122].
Activation of endothelial cells by inflammatory cytokines pro-
foundly alters the balance between t-PA and PAI-I synthesis by
reducing t-PA and dramatically increasing PAI-I expression and
synthesis [120, 123, 124]. In addition, PAI-I markedly relocalizes
from the subendothelial compartment to the endothelial cell
surface [125]. Thrombin induces PAI-I synthesis [126] and there-
fore participates in preventing fibrin degradation during endothe-
lial-cell activation. Thus, in conjunction with other mechanisms
already discussed, the alteration in the balance between cell-
surface t-PA and PAI-I activity during endothelial cell activation
promotes fibrin deposition.
The Schwartzman reaction, produced by two consecutive infu-
sions of endotoxin, results in massive intravascular coagulation,
glomerular capillary occlusion with fibrin and, when severe, acute
cortical necrosis. Endotoxin infusion in rats markedly reduces
t-PA and increases PAI-I expression in renal vessels [125], and
infusion of t-PA markedly reduces glomerular fibrin deposits after
induction of the Schwartzman reaction in rabbits [127].
In the normal kidney, t-PA is expressed primarily in glomeruli,
and PAI-I expression is usually low [128]. A significant induction
of renal glomerular and vascular PAI-I mRNA and immunoreac-
tivity has been found in MRL/lpr mice with active lupus nephritis
[129]. In anti-GBM-antibody-mediated glomerulonephritis, t-PA
diminished and PAI-I activity increased in glomeruli during the
autologous phase of the disease, when fibrin deposition also was
significant [130]. Evidence also favors reduced fibrinolytic activity
in human glomerulonephritis [131], and an uncontrolled study has
suggested a therapeutic effect of ancrod, a fibrinolytic venom
toxin, in some patients with glomerulonephritis [132].
Endothelial cell activation in the hemolytic-uremic syndrome
The thrombotic microangiopathies represent a cluster of dis-
ease syndromes in which endothelial cell activation is central.
Hemolytic-uremic syndrome, thrombotic thrombocytopenic pur-
pura, the sequelae of malignant hypertension and scleroderma
crisis, and pre-eclampsia/eclampsia syndromes are seen most
commonly. When the hemolytic-uremic syndrome occurs in chil-
dren, the most frequent cause is a bacterial toxin released by
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diarrhea-causing organisms. Hemolytic-uremic syndrome also can
be related to treatment with chemotherapeutic agents and to
cyclosporine A administration. The proximate cause of endothe-
lial cell activation and platelet thrombus formation in the remain-
der of the patients with hemolytic-uremic syndrome and throm-
botic thrombocytopenic purpura as well as other thrombotic
microangiopathies is unknown.
Shiga-like verotoxins are responsible for approximately 50% of
cases of childhood hemolytic-uremic syndrome [91]. It is generally
held that endothelial-cell activation, with the release of vWF,
consequent platelet aggregation, and increased endothelial ex-
pression of PAI-I, is central to the hematologic abnormalities and
renal failure observed in this disease. Circulating PAI-I levels are
markedly increased in patients with active hemolytic-uremic syn-
drome [133, 134]; this increase is consistent with endothelial-cell
activation. Indeed in human renal microvascular endothelial cells,
PAI-I expression rises dramatically in response to Shiga toxin
[135]. The globotriaosylceramide (GB3) receptor for Shiga and
Shiga-like toxins is found on human microvascular endothelial
cells in vitro, and its expression is markedly induced in other
endothelial cells by inflammatory cytokines [136]. However, glo-
merular GB3 receptors in human tissues are detected only in low
numbers during infancy, and not at all in adults. Instead, GB3
Shiga-toxin receptors are most abundant in proximal tubular
epithelial cells [137]. It is also of interest that intraperitoneal
injection of Shiga toxin in mice produced pronounced tubular
epithelial cell damage and induced the TNFa promoter in kid-
neys, but not in other organs [138]. Circulating TNFa levels
increase in children with the hemolytic-uremic syndrome [139],
and Shiga toxin as well as Shiga-like toxin can activate monocytes
to produce TNFa [140]. One therefore can conclude that al-
though Shiga toxin and Shiga-like toxins directly activate endo-
thelial cells expressing GB3 receptors, other cell types, including
renal tubular epithelial cells and monocytes, are also vulnerable to
these toxins. Furthermore, inflammatory cytokines probably par-
ticipate in the response to these toxins by inducing GB3 expres-
sion in endothelial cells. In the case presented here, the clinical
presentation of thrombocytopenia, hemolysis, and anuric acute
renal failure, together with the findings of endothelial cell activa-
tion on biopsy, suggest the diagnosis of the hemolytic-uremic
syndrome. The bacteremia and prompt response to antibiotic
therapy, together with the interstitial nephritis, suggest that the
underlying disease was infection related. It is not known to what
degree inflammatory cytokines and/or bacterial toxins were re-
sponsible in causing endothelial cell activation. Although one
isolate of Enterobacter cloacae has been described to produce
Shiga-like toxin II [141], the related species Enterobacter aero-
genes, isolated in this case, has not. Thus, in the case presented,
endothelial cell activation with consequent platelet consumption
is probably best explained by high levels of intrarenal endotoxin
and/or inflammatory cytokine production. Nevertheless, the case
demonstrates the clinical features of both pro-coagulant and
pro-inflammatory endothelial cell activation. As I said, massive
mobilization of vWF and P-selectin by calcium-mobilizing ago-
nists is likely to play the predominant role in platelet thrombus
formation, so common in patients with thrombotic microangiog-
raphy, while recruitment of inflammatory cells is mediated by a
different NFkB-dependent mechanism and is reflected in this case
by interstitial leukocyte infiltration.
Conclusion
In summarizing the cell biology of endothelial cell activation, it
becomes evident that inflammatory cytokines are central both in
converting endothelium into a pro-coagulant surface and in
recruiting leukocytes. However, in examining clinical material, it
is also readily apparent that endothelial cell activation can have
very different histopathologic consequences depending on the
underlying disease. There seems to be more than one activated
endothelial cell phenotype. Platelet aggregation and endothelial
cell swelling predominate in the hemolytic-uremic syndrome,
while leukocyte recruitment predominates when there is antigen-
antibody-mediated complement activation, or infection. It is
known that mediators that activate the calcium signaling cascade
induce Weibel-Palade body mobilization without activation of
leukocyte recruitment, while cytokines are necessary to activate
other pro-coagulant functions and leukocyte recruitment. Cyto-
kine release is, however, a feature of all inflammatory diseases in
which endothelial cell activation is observed, including the hemo-
lytic-uremic syndrome. Mechanisms that determine whether en-
dothelial cells exhibit predominantly one or the other activated
phenotype are currently not understood. The challenge in unrav-
eling the pathobiology of idiopathic hemolytic-uremic syndrome,
thrombotic thrombocytopenic purpura, and the pregnancy-asso-
ciated forms of endothelial cell activation probably lies in solving
this riddle.
QUESTIONS AND ANSWERS
DR. JOHN T. HARRINGTON (Dean, Tufts University School of
Medicine, Boston, Massachusetts): You alluded to an interaction
between P-selectin and leukocytes. What is the molecular mech-
anism of P-selectin-mediated adhesion, and what binds to this
receptor?
DR. BALLERMANN: The selectins, P-selectin, E-selectin, and
L-selectin, are lectin-like cell-surface receptors that bind highly
glycosylated ligands, also referred to as mucins, on opposing cells.
Both P- and E-selectin are expressed by endothelial cells; L-
selectin is found predominantly on lymphocytes. P-selectin is
stored in endothelial cell granules, the Weibel-Palade bodies,
which also contain von Willebrand factor. Upon endothelial cell
activation with calcium-mobilizing agonists, P-selectin rapidly
moves to the cell membrane. Transcription of E-selectin is
stimulated by inflammatory cytokines. Both P- and E-selectin bind
their counterreceptors on leukocytes, for example, PSGL in the
case of P-selectin [142]. This binding results in low-affinity adhe-
sion and rolling of leukocytes on the endothelium. Subsequent
higher-affinity interactions with cell adhesion molecules allow the
leukocytes to spread and to transmigrate across the endothelium.
DR. KEVIN ROSSITER (Johns Hopkins University School of Med-
icine, Bayview Medical Center, Baltimore, Maryland): While some
diseases, for instance, diarrheal illnesses due to E. coli strain
0157:H7, are frequently associated with the hemolytic-uremic
syndrome, the factors that can activate endothelial cells must be
present in every case of inflammation or infection. Yet thrombotic
microangiopathy is rare in most cases of infection. What natural
brakes are there on these mechanisms of endothelial cell activa-
tion? Would these mechanisms have played a role in the patient
discussed today?
DR. BALLERMANN: You are asking a very important question.
Clearly, in most cases of infection or inflammation, endothelial
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cell activation is a local phenomenon, insufficient to cause sys-
temic platelet or fibrinogen consumption. Endothelial cell activa-
tion in such cases is a normal component of immune function. The
mechanisms that return the endothelium to the non-activated,
quiescent phenotype have not been well studied. In part, they
relate to the dissipation of inflammatory cytokines and chemo-
kines, and in part to the desensitization of endothelial cells to
these mediators. Evidence also indicates that transforming growth
factor beta participates in dampening the response of endothelial
cells to inflammatory cytokines [143].
Overwhelming sepsis is accompanied by massive systemic en-
dothelial cell activation, with consumption of platelets, coagula-
tion factors, and fibrinogen, and with the appearance of fibrin
degradation products in the circulation. Microthrombi composed
of fibrin and platelets form in many microvessels. In the kidney,
these thrombi can lead to acute cortical necrosis. Endothelial cell
activation in such cases of disseminated intravascular coagulation
results from the presence of circulating bacterial coat materials—
for instance, lipopolysaccharide, bacterial toxins, and inflamma-
tory cytokines—all of which are powerful activators of procoagu-
lant activity in endothelium. Treatment of the infection is
sometimes effective in rapidly reversing the ongoing intravascular
coagulation; this suggests that endothelial cell activation is only
sustained when bacterial toxins and cytokines continue to be
produced.
In about 50% of children with the hemolytic-uremic syndrome,
the causative infectious agent can be identified [91]. As I discussed
earlier, in these cases, Shiga-like toxins activate endothelial cells
expressing the GB3 receptor, and TNFa amplifies the response
augmenting endothelial GB3 expression. In the hemolytic-uremic
syndrome, endothelial cells seem to release von Willebrand factor
and mobilize P-selectin in preference to other components of the
endothelial cell activation cascade. This phenomenon is evidenced
by the presence of platelet thrombi without massive fibrin depo-
sition or inflammatory cell infiltration in glomerular or peritubu-
lar capillaries. Inhibition of intravascular coagulation with heparin
and anti-platelet agents or with thrombolytics have not proven
effective, however. Thus microvascular platelet thrombus forma-
tion likely is not simply a self-perpetuating process; rather, there
must be continued endothelial cell activation. Currently, it is not
known why endothelial cell activation with platelet consumption
and hemolysis is relatively long-lived in the infection-related
forms of hemolytic-uremic syndrome.
In patients with idiopathic hemolytic-uremic syndrome or
thrombotic thrombocytopenic purpura, the mechanisms that lead
to endothelial cell activation are still undefined. Circulating,
large-molecular-weight forms of von Willebrand factor have been
reported in such cases. This finding suggests sustained release of
the contents of Weibel-Palade bodies from the endothelium, or
reduced von Willebrand factor degradation. Reduced tissue factor
pathway inhibitor expression might represent another mechanism
operating in the thrombotic microangiopathies [114, 117]. To
what degree aberrations in this system participate in the patho-
genesis of the thrombotic microangiopathies is incompletely un-
derstood, however. Nevertheless, treatment with plasma ex-
change, presumably to supply necessary factors to reverse the
hypercoagulable state, is effective in treating these disorders.
Once these factor(s) in plasma are identified, we may gain a better
understanding of the mechanisms that return the endothelium to
the non-coagulable state.
In the case presented today, which I chose precisely because the
clinical presentation suggested hemolytic-uremic syndrome in an
unusual setting, I postulate that the massive infectious interstitial
nephritis accounted for endothelial cell activation in glomeruli.
But, as you point out, we rarely encounter the hemolytic-uremic
syndrome in patients with pyelonephritis. Although the patient
did not exhibit the classic features of disseminated intravascular
coagulation and had no evidence for overwhelming sepsis, I still
think it is possible that this patient represents a clinical variant of
disseminated intravascular coagulation, which was interrupted
with antibiotic therapy. The alternative explanation, that the
bacterium responsible for her pyelonephritis could have produced
a toxin in the family of Shiga toxins, also cannot be ruled out. In
this regard, one clinical report demonstrated that an isolate of
Enterobacter cloacae produced Shiga-like toxin II [141], but En-
terobacter aerogenes, a distinct species found in this case, has not
been reported to produce such toxins.
DR. RACUSEN: Was von Willebrand factor measured in this
patient? How specific and useful is it as a clinical marker of the
hemolytic-uremic syndrome?
DR. BALLERMANN: The examination of von Willebrand factor
multimer size in plasma is a research tool that is not generally
used as a clinical test for the hemolytic-uremic syndrome. Unusu-
ally large multimers of von Willebrand factor have been found in
patients with recurrent idiopathic hemolytic-uremic syndrome and
thrombotic thrombocytopenic purpura when they are in remis-
sion, not usually during the active phase of the disease. The
diagnosis of the hemolytic-uremic syndrome usually is made when
one observes hemolysis, platelet consumption, schistocytes on the
blood smear, and renal failure. Because of overlap in the clinical
presentation of the hemolytic-uremic syndrome and disseminated
intravascular coagulation, bacterial sepsis must be ruled out, and
the presence of fibrin degradation products must be sought. The
presence of plasminogen activator inhibitor in the serum of these
patients seems to be a very good marker of massive endothelial
cell activation, and it could be used as a clinical tool [133].
Currently, though, it too is not used as a routine test.
DR. HARRINGTON: Why does t-PA not work in hemolytic-uremic
syndrome if endothelial cell activation is the underlying mecha-
nism of disease?
DR. BALLERMANN: I suspect that multiple mechanisms are
activated at the level of the endothelium, and that expression of
plasminogen activator inhibitor is not the predominant one. It
seems clear that fibrin deposition is not the major cause of
intravascular coagulation in the hemolytic-uremic syndrome, but
that platelet aggregation and platelet thrombi are the main
culprits.
DR. PAUL J. SCHEEL (Director of Clinical Nephrology, Johns
Hopkins University School of Medicine): If cytokine-mediated
activation of endothelial cells is the initiating event that triggers
endothelial cell procoagulant activity, does this simply imply that
we should be using glucocorticoids to modify the course of
disease?
DR. BALLERMANN: To answer your question, it probably is best
to separate sepsis-related endothelial cell activation from that
observed in the hemolytic-uremic syndrome. In the patient pre-
sented here, steroid therapy was indeed initiated before it became
clear that the underlying disease was Enterobacter aerogenes-
induced urosepsis. Steroids were stopped, and antibiotic therapy
was sufficient to reverse the hemolysis and thrombocytopenia. In
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patients with infection, I think steroids should be used with great
caution.
In cases of idiopathic hemolytic-uremic syndrome and throm-
botic thrombocytopenic purpura, steroid therapy does seem to
have a beneficial effect. As you know, Dr. William Bell at this
institution routinely uses corticosteroids in the treatment of these
patients [144]; in conjunction with repeated plasma exchange
during the active phase of the disease, this approach seems to
provide a benefit. Steroids probably reduce the production of
inflammatory cytokines, although other direct effects on the
endothelial cells also are possible. In addition, a factor in plasma
that is absent, or present in insufficient quantities, in these
patients seems to be necessary to halt the process of intravascular
platelet aggregation. Thus, plasma exchange is an important
component of therapy. Whether plasma exchange replaces a
factor that increases von Willebrand factor degradation, or
whether it supplies tissue factor pathway inhibitor or an as-yet-
unidentified agent that in some way “turns off” the endothelium is
not known.
DR. ROSSITER: Would you address the subject of endothelial cell
activation by inflammatory cytokines in the context of renal
transplantation? Intercurrent infection seems to adversely affect
the outcome of rejection episodes. Is this related to endothelial
cell activation?
DR. BALLERMANN: It is fair to say that any stimulus, like
infection, that leads to endothelial cell activation theoretically can
aggravate immune-mediated phenomena like rejection because at
least some of the effector mechanisms—for instance, leukocyte
recruitment—would be amplified. There is evidence, in particular,
that CMV infection in renal transplant patients augments expres-
sion of MHC class-II antigens during rejection episodes [145], and
that this heightened expression could increase cell-mediated
rejection. Also, C5a production in the kidney and leukocyte
adhesion molecule shedding during transplant rejection are aug-
mented by concurrent CMV infection [146]. However, we do not
have clear-cut evidence that endothelial cell activation plays the
central role in these phenomena. Indeed, viral infection of
endothelial cells stimulates MHC class-I, but inhibits MHC
class-II, expression; this suggests that renal MHC class-II induc-
tion by viral infection is not an endothelial cell phenomenon [147,
148].
It has also been suggested that chronic transplantation-associ-
ated arteriopathy, which probably accounts for much of the
chronic progressive loss of renal function post transplantation
(also referred to as chronic rejection), could be aggravated by
CMV infection. In patients with cardiac transplants, chronic CMV
infection seems to accelerate graft arteriosclerosis [149]. In the
kidney, however, a causal relationship between CMV infection
and endothelial-cell-mediated vascular remodeling has not been
proven. Also, although chronic CMV infection has been postu-
lated to play a role in transplant glomerulopathy, such an associ-
ation could not be confirmed [150].
DR. HARRINGTON: You touched only briefly on the role of
endothelial-cell-derived vasoactive mediators during activation.
Could you expand on the effects of endothelial cell activation on
nitric oxide synthesis and its impact on renal hemodynamics?
DR. BALLERMANN: The effect of endothelial cell activation by
the inflammatory cytokines TNFa and interleukin-1b on the nitric
oxide cascade has been examined in many studies. The endothe-
lial-cell-specific nitric oxide synthase (eNOS) is a constitutively
expressed enzyme activated by calcium mobilizing agonists and by
receptor tyrosine kinase ligands, for instance, vascular endothelial
cell growth factor. Upon endothelial cell activation with TNFa,
eNOS mRNA becomes highly unstable [96, 151], causes eNOS
levels to drop, and reduces the ability of the cells to respond to the
usual activators with NO release. The reduction in eNOS expres-
sion would tend to increase renal vascular resistance. However,
the inflammatory cytokines also stimulate transcription of iNOS
[152]. Expressed in greatest abundance by macrophages, this NOS
isoform also is induced by inflammatory cytokines in mesangial
cells [153], vascular smooth muscle cells, and endothelial cells
[152]. Thus, in activated endothelial cells, NO production from
iNOS tends to be high and sustained, while regulated NO
synthesis from eNOS is not observed. In sepsis, there is no doubt
that high levels of vascular NO synthesis contribute to systemic
vasodilation. High rates of NO synthesis also have been noted in
patients with thrombotic microangiopathies; this finding is consis-
tent with endothelial cell activation [154].
DR. HARRINGTON: Using that information, can the NOS system
be interrupted or modulated therapeutically?
DR. BALLERMANN: A number of investigators have interrupted
NO synthesis in sepsis. The results have been variable. In some
reports, renal perfusion improved with the increased systemic
vascular resistance and amelioration of hypotension, but in other
reports renal blood flow fell with NOS inhibition, presumably
because intrarenal NO synthesis also was inhibited [155, 156].
Evidence in experimental animals also indicates that NO synthesis
inhibition can have a detrimental effect on survival, as macro-
phage NO serves a bacteriocidal function [157]. At this juncture,
highly specific NO synthase inhibitors have not been developed
and, given the need for bacteriocidal NO in sepsis, effective
therapy might be better aimed at the NO signaling cascade. The
effect of transforming growth factor b1 on NOS expression also
has been examined. TGF-b1 increases eNOS and inhibits iNOS
expression [97, 104]. In cardiac myocytes, TGF-b1 inhibits iNOS
expression in response to inflammatory cytokines and protects the
cells from NO-induced cytotoxicity [158]. In experimental lipo-
polysaccharide-induced septic shock, TGF-b1 infusion resulted in
less hypotension and improved survival [159]. TGF-b1 reverses
several components of inflammatory cytokine-stimulated endo-
thelial cell activation [143], so it will be of great interest to see
whether TGF-b1 infusion will have broader therapeutic applica-
bility.
DR. RACUSEN: When we examined the kidneys in this case, it
was clear that endothelial cells were not the only injured cellular
element. The glomerular epithelial cells also showed injury (Fig.
1B). There have been reports of circulating cytokines or presumed
cytokines that can increase glomerular capillary wall permeability.
After her GFR and urine output improved, did your patient have
any evidence of proteinuria?
DR. BALLERMANN: Proteinuria is common when thrombotic
microangiopathy involves glomerular capillary endothelial cells. A
host of mediators can alter glomerular permselectivity, among
them the membrane attack complex of complement, metallopro-
teinases, neutrophil-derived enzymes, and probably also high
levels of NO. However, the precise mediators responsible for
altering the permselectivity of the glomerular capillary wall in
patients with thrombotic microangiopathy, or in other renal
diseases for that matter, have not been identified [160]. Virginia
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Savin and her colleagues recently reported a glomerular perme-
ability factor in the serum of patients with focal and segmental
glomerular sclerosis [161], but this factor has not yet been
characterized at the molecular level. Our patient had significant
proteinuria after urine flow commenced. However, we did not
quantitate the degree of proteinuria, nor did we determine the
relative contribution of albumin. Given the abundance of leuko-
cytes in the urine, I cannot say to what degree the proteinuria
reflected a persistent glomerular capillary wall defect.
DR. GREGORY G. GERMINO (Department of Nephrology, Johns
Hopkins University School of Medicine): Glomerular endothelial
cell injury also occurs in patients with pre-eclampsia and preg-
nancy-associated hemolytic-uremic syndrome. What is known
about the mediators of endothelial injury in those patients?
DR. BALLERMANN: Yes, there is marked glomerular endothelial
cell swelling in patients with pre-eclampsia. At times this swelling
obliterates the lumen of glomerular capillaries [162]. This form of
endothelial cell activation also is associated with severe protein-
uria and hypertension. It is now accepted that endothelial cell
activation and injury is central to the spectrum of pre-eclampsia,
eclampsia, and the HELLP syndrome (hemolysis, erythrocyte
fragmentation, liver enzyme abnormalities, and low platelet
count). Pre-eclampsia is associated with inadequate invasion of
uterine spiral arteries by cytotrophoblasts and failure of these cells
to differentiate into endothelial cells [163]. It is conceivable that
uterine mediators that stimulate cytotrophoblast invasion and
differentiation in some way also affect non-uterine endothelial
cells in this disease. Indeed, since delivery of the products of
conception reverses the eclampsia syndromes, the mediators that
cause endothelial cell activation in these syndromes are likely to
be derived from the placenta or uterus. Hemolytic-uremic syn-
drome and thrombotic thrombocytopenic purpura also can de-
velop during pregnancy, and the hemolytic-uremic syndrome has
been reported in a number of patients during the first month after
delivery [164]. While the HELLP syndrome clearly is related to
the process of pre-eclampsia, hemolytic-uremic syndrome and
thrombotic thrombocytopenic purpura appear to be distinct, as
they commonly occur in women who have no evidence of pre-
eclampsia. While all these conditions have as their underlying
pathophysiologic process some form of endothelial cell activation,
the mediators involved have remained elusive. Nevertheless,
successful treatment with plasma exchange has been reported in
pregnancy-associated thrombotic thrombocytopenic purpura
[165]; mechanisms similar to those in non-pregnant patients thus
may be at work.
DR. TIBOR NADASDY (Department of Pathology, Johns Hopkins
University School of Medicine): Thrombotic microangiopathy is a
heterogeneous disorder affecting predominantly glomerular cap-
illary endothelium in some patients, for instance, those with
diarrhea-associated hemolytic-uremic syndrome. Or it can spare
glomerular vessels and involve predominantly small arteries and
arterioles instead, for instance, in patients with atypical hemolytic-
uremic syndrome or thrombotic thrombocytopenic purpura. The
former seems to be related to infection and tends to recover, while
thrombotic microangiopathy involving small arteries and arte-
rioles is not related to infection and usually does not recover. Can
you comment on the heterogeneity of endothelial cell involvement
in the various forms of thrombotic microangiopathy?
DR. BALLERMANN: I am glad you asked this question. The point
I tried to make in my presentation today is that many causes of
endothelial cell activation result in a spectrum of predictable
clinical findings, even though the causes of endothelial cell injury
and activation are diverse and in most cases not well understood.
Mediators of endothelial cell activation that are well described
include bacterial toxins (like lipopolysaccharide), Shiga toxin and
Shiga-like toxins, and inflammatory cytokines. In other conditions,
for instance, malignant hypertension, scleroderma, the idiopathic
(or atypical) forms of hemolytic-uremic syndrome, and throm-
botic thrombocytopenic purpura, and in pregnancy-associated
endothelial cell activation, the mechanisms of endothelial cell
activation are unknown. Which endothelial bed is affected seems
to depend in part on the source of activating mediators, whether
they become systemic or not, and on the ability of endothelial cells
to respond to them. The phenotype of endothelial cells varies
dramatically from vessel to vessel, so that not all endothelial cells
are subject to the same mechanisms of injury. For instance, in the
diarrhea-associated forms of hemolytic-uremic syndrome, also
referred to as typical HUS, Shiga- and Shiga-like toxins appear to
target glomerular capillary endothelial cells in preference to other
endothelial cell beds. Recent observations suggest that proximal
tubule cells are particularly rich in the receptor for these toxins,
and that they release inflammatory cytokines that in turn upregu-
late GB3 expression on endothelial cells locally. Because recep-
tors for Shiga- and Shiga-like toxin remain confined largely to
tubular epithelium and glomerular endothelium, it is not difficult
to imagine why the disease affects primarily the renal glomerular
endothelium and not other blood vessels.
The idiopathic (atypical) form of hemolytic-uremic syndrome
and thrombotic thrombocytopenic purpura seem to be related
syndromes, distinguished from each other principally by the
distribution of blood vessel involvement. Glomeruli are more
often spared, and preglomerular arteries and arterioles involved,
in patients with thrombotic thrombocytopenic purpura. Although
endothelial cell injury is thought to be the initiating event in these
diseases, the mechanisms are not known, and therefore it is
difficult for me to speculate on why the distribution of blood
vessel involvement in this set of diseases is different than that in
the typical, diarrhea-associated form of hemolytic-uremic syn-
drome.
With regard to the thrombotic microangiopathies involving
predominantly non-glomerular vessels, these are commonly ob-
served in patients with malignant hypertension and scleroderma
crisis. Histopathologic examination usually shows afferent arterio-
lar endothelial injury and sparing of glomerular capillaries. In
these cases, it is very likely that the mechanism of endothelial cell
injury differs from that in the glomerular forms of thrombotic
microangiopathy and that it involves mechanical factors or intense
local vasoconstriction. In these cases, hemolysis and thrombocy-
topenia usually are less marked than in patients with hemolytic-
uremic syndrome, and treatment centers around aggressive con-
trol of hypertension.
DR. MILAGROS SAMANIEGO (Senior Fellow in Nephrology, Johns
Hopkins University School of Medicine): A hemolytic-uremic-like
syndrome is also described in antibody-mediated diseases, mostly
in patients with severe systemic lupus erythematosus and an-
tiphospholipid antibody syndrome. What is the role of antibodies
in the hemolytic-uremic syndrome?
DR. BALLERMANN: Clearly antibodies play a role in mediating
some forms of vasculitis as well as blood vessel injury in some
patients with scleroderma. This form of endothelial cell activation
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is manifested predominantly by neutrophil recruitment and neu-
trophil-mediated vessel wall damage. For example, in ANCA-
associated vasculitis, proteinase 3 or myeloperoxidase, both re-
leased from neutrophil granules, can associate with the
endothelial cell glycocalyx. The interaction of antibodies with
these antigens is sufficient to activate complement and to cause
endothelial cell injury and activation. So in antibody-mediated
disease, neutrophil accumulation and vessel wall destruction are
commonly found; this is not usually the case in the thrombotic
microangiopathies. While the hemolytic-uremic syndrome is not a
common presentation in patients with systemic lupus erythema-
tosus, such cases have been reported [166], and anti-phospholipid
antibodies have been implicated. Whether the autoantibodies
interact predominantly with endothelial cells or with platelets in
these cases is unknown. Furthermore, it is not known whether the
autoantibodies in these cases are causally related to endothelial
cell activation, or whether they are a consequence of endothelial
cell injury. In patients with thrombotic thrombocytopenic purpura
of unknown cause, antibodies against renal microvascular endo-
thelial cells also have been identified [167] but, as in the rare cases
of lupus-associated thrombotic microangiopathy, these antibodies
may well represent a consequence, rather than a cause, of
endothelial cell injury.
DR. LUIZ GIMENEZ (Director, Renal Division, Good Samaritan
Hospital, Baltimore): Are you aware whether angiotensin II mod-
ulates endothelial cell function and activation? I ask this question
because it is my understanding that in the pre-eclampsia syn-
drome the relative vascular insensivity to angiotensin II of preg-
nancy is lost. Could angiotensin II play a role in endothelial cell
injury in this situation?
DR. BALLERMANN: Endothelial cells have receptors for angio-
tensin II and probably also for other angiotensin fragments. These
receptors stimulate the release of the vasodilators prostacyclin
and NO, which serve to dampen the vasoconstrictor response to
angiotensin II [168, 169]. The relative insensitivity of pregnant
women to angiotensin II is related to increased production of
vasodilatory prostaglandins, among them endothelial-cell-derived
prostacyclin. Pregnancy also is attended by a significant upregu-
lation of angiotensin II receptors on uterine, but not systemic,
endothelial cells, with a consequent increase in local vasodilator
production [170]. In pre-eclampsia, the balance of vasoconstric-
tors to vasodilators is lost, at least in part because of overproduc-
tion of thromboxane A2 and endothelin-1. It is of note that
activated endothelial cells induce platelets to release thrombox-
ane, and they themselves produce large amounts of endothelin-1.
Induction of uterine angiotensin II receptors is not observed in
pre-eclampsia, possibly because cytotrophoblasts fail to transdif-
ferentiate into endothelial cells. However, it is doubtful that the
uterus’ failure to upregulate angiotensin II receptors is causally
related to endothelial cell injury during pre-eclampsia. In fact, I
am not aware of any evidence that causally links angiotensin II to
endothelial cell activation, either in pre-eclampsia or in non-
pregnant humans. I suspect that endothelial cell activation is
instead responsible for the increased responsiveness to the vaso-
constrictor actions of angiotensin II in women with pre-eclampsia
syndromes.
DR. HARRINGTON: This question is for Dr. Racusen. In the case
presented today, the biopsy showed significant interstitial inflam-
mation, but I am nevertheless struck by the discrepancy between
the minimal pathologic changes in the glomeruli and the profound
oligoanuria, which lasted at least two weeks. In patients with
HUS, is there any relationship between the changes in the
glomerulus and renal function?
DR. RACUSEN: Certainly there are relationships between the
pathologic appearance and the ultimate prognosis, but these are
not very strong. Often, lack of correlation is ascribed to sampling
error. When glomerular capillary microthrombus formation is
severe, however, the GFR is almost always profoundly reduced. In
this case, the kidney was examined 6 days after the hemolysis had
resolved. It is therefore conceivable that the pathologic lesion in
the glomeruli had regressed by the time the kidney was examined.
DR. HARRINGTON: But she was still anuric when the biopsy was
performed.
DR. RACUSEN: That’s right, but she was in recovery in terms of
acute endothelial insult. The hemolysis and thromboctyopenia
had resolved completely. I think that we have to suppose that
there either were some residual functional hemodynamic changes
resulting in the low GFR, or that the tubulointerstitial process,
possibly combined with the cast formation (which was quite
extensive), had the greater effect on renal function.
DR. NADASDY: In regard to the relationship between pathologic
findings and renal function in the hemolytic-uremic syndrome and
thrombotic thrombocytopenic purpura, at a meeting of the Ger-
man Society of Nephrology in Koblenz several years ago, Bohle
and colleagues presented data on 195 patients with the clinical
diagnosis of HUS and acute renal failure [171]. In 23 of these
patients, they observed changes consistent with acute tubular
necrosis but no evidence of glomerular capillary or arterial injury.
Loss of renal function therefore does not seem to correlate strictly
with the severity of glomerular lesions, and can be caused by acute
tubular necrosis.
DR. SAMANIEGO: Barbara, as did today’s patient, a large number
of patients with the hemolytic-uremic syndrome or thrombotic
thrombocytopenic purpura require dialysis. I believe evidence
shows that the type of dialysis membrane can have a significant
effect on the recovery of patients with acute renal failure.
Membrane incompatibility results in cytokine release, so it is
tempting for us to speculate that this could further aggravate
endothelial cell activation in patients with hemolytic-uremic syn-
drome. Do you have any information regarding membrane bioin-
compatibility in these patients?
DR. BALLERMANN: Cellulosic dialysis membranes do lead to
complement activation and adhesion molecule expression on
leukocytes, with consequent sequestration of the cells primarily in
the pulmonary circulation. However, I am not aware of any
studies in which the impact of bio-incompatible membranes on
the outcome of the hemolytic-uremic syndrome was studied.
DR. HARRINGTON: Dr. Scheel, do you have any thoughts on this
issue?
DR. SCHEEL: Raymond Hakim has done a large amount of work
examining membrane biocompatibility in acute and chronic renal
failure [172]. He and Dr. Himmelfarb have reported both clinical
and histologic evidence that in acute renal failure, the use of
biocompatible membranes results in a more favorable outcome.
Like Barbara, I am not aware that such studies have included
patients with renal failure due to endothelial cell disease. I would
be surprised if such data existed, as such cases are so much rarer
than those with acute ischemic renal failure, and experimental
models of endothelial cell injury are not readily available.
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